MedTrace Logo

Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)

NCT01079182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4681

Last updated 2015-07-09

Study results available
· View outcomes & findings →

Summary

The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.

Conditions

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Bianca Wittig, MD · AbbVie Deutschland GmbH & Co. KG, Medical Department

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2014-05-31
Completion
2014-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079182 on ClinicalTrials.gov